DongKoo Bio & Pharma Co. Ltd. Cash Flow-to-Debt Ratio
DongKoo Bio & Pharma Co. Ltd. cash flow-to-debt ratio. DongKoo Bio & Pharma Co. Ltd. (006620) has a Cash Flow-to-Debt Ratio of 0.03x as of June 2026, meaning its operating cash flow of ₩4.46 Billion could theoretically repay 0% of its total liabilities (₩176.02 Billion) in one year. Check 006620 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of DongKoo Bio & Pharma Co. Ltd. (2015–2025)
Cash flow-to-debt ratio of DongKoo Bio & Pharma Co. Ltd. from 2015 to 2025. Historical debt coverage capacity for DongKoo Bio & Pharma Co. Ltd. across 11 annual periods. Check DongKoo Bio & Pharma Co. Ltd. (006620) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
DongKoo Bio & Pharma Co. Ltd. Cash Flow-to-Debt Ratio by Year (2015–2025)
DongKoo Bio & Pharma Co. Ltd. cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for DongKoo Bio & Pharma Co. Ltd.. For the full cash flow conversion analysis, see cash efficiency ratio of DongKoo Bio & Pharma Co. Ltd..
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.02x | ₩-4.29 Billion | ₩184.19 Billion | ▼ -118.6% |
| 2024 | 0.13x | ₩17.34 Billion | ₩138.73 Billion | ▲ +181.3% |
| 2023 | 0.04x | ₩3.59 Billion | ₩80.66 Billion | ▼ -81.5% |
| 2022 | 0.24x | ₩16.82 Billion | ₩69.95 Billion | ▼ -26.6% |
| 2021 | 0.33x | ₩17.90 Billion | ₩54.66 Billion | ▲ +117.4% |
| 2020 | 0.15x | ₩7.49 Billion | ₩49.70 Billion | ▼ -30.0% |
| 2019 | 0.22x | ₩10.14 Billion | ₩47.07 Billion | ▲ +976.1% |
| 2018 | -0.02x | ₩-791.20 Million | ₩32.18 Billion | ▼ -109.8% |
| 2017 | 0.25x | ₩9.51 Billion | ₩37.85 Billion | ▼ -13.7% |
| 2016 | 0.29x | ₩12.59 Billion | ₩43.27 Billion | ▲ +144.3% |
| 2015 | 0.12x | ₩6.93 Billion | ₩58.22 Billion | — |